Nordion is a global health science company that provides market-leading products and services used for the prevention, diagnosis and treatment of disease. http://www.nordion.com http://www.nordion.com/images/mds-nordion.gif http://www.nordion.com Nordion to Release Fourth Quarter and Fiscal 2013 Financial Results http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1883553 Tue 10 Dec 2013 10:10:00 EST Nordion Shares How the Science of Irradiation is Solving Today’s Unique Global Product Challenges http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsArticle&ID=1871712 Mon 4 Nov 2013 08:16:00 EST Capability Opens New Market Opportunities to Ultra-Low Power Memory Products http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsArticle&ID=1864972 Wed 16 Oct 2013 09:16:00 EST Nordion Inc. (TSX:NDN) (NYSE:NDZ) has reached an agreement to settle claims filed against Nordion and its subsidiaries by BioAxone BioSciences, Inc. (“BioAxone”) for a nominal amount. The parties are finalizing the settlement documents, which are expected to be confidential. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsArticle&ID=1857359 Tues 24 Sept 2013 11:01:00 EST Nordion Inc. (TSX:NDN) (NYSE:NDZ) today announced that the Company is scheduled to report its third quarter 2013 financial results before markets open on September 5, 2013. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1850619 Thu 29 Aug 2013 08:01:00 EST Nordion Inc. (TSX:NDN) (NYSE:NDZ) announced today that Nordion and Atomic Energy of Canada Limited (“AECL”) have entered into a comprehensive settlement agreement to resolve the outstanding claims between both parties related to the MAPLE facilities. Nordion has also announced that, effective immediately, the parties have entered into an amended and restated isotope supply agreement and a waste management services agreement. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1848627 Tue 20 Aug 2013 11:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services to the global health science market, today reported results for the second quarter of fiscal 2013. The Company generated $56.1 million in revenue for the second quarter fiscal 2013, an increase of $6.1 million, or 12%, over revenue of $50.0 million for the same period in fiscal 2012. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1827485 Wed 05 Jun 2013 17:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, announced that it has entered into an agreement to divest its Targeted Therapies business to BTG plc (LSE: BTG) ("BTG"), an international specialist healthcare company based in London, United Kingdom, for a cash purchase price of US$200 million. Net of cash taxes and transaction costs, Nordion expects to realize approximately US$185 million on closing. The transaction is anticipated to be completed by the end of June 2013. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1823548 Thu 23 May 2013 02:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services for the prevention, diagnosis and treatment of disease, will host two upcoming educational and scientific meetings to support the growth and expansion of TheraSphere treatment in Europe. On April 11 – 12, Nordion will host its 3rd European TheraSphere User Group Meeting in Vienna, Austria and on April 18, Nordion will offer a Satellite Symposium at the 3rd Interdisciplinary Treatment of Liver Tumors (ITLT) Meeting in Essen, Germany. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1804511 Tue 09 Apr 2013 08:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services to the global health science market, has settled claims filed against Nordion by Dr. Reddy's Laboratories Ltd. and certain affiliated companies ("Dr. Reddy's"). Details of the settlement are confidential. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1799068 Thu 21 Mar 2013 07:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) a leading provider of products and services to the global health science market, today reported results for the first quarter of fiscal 2013. The Company generated $53.7 million in revenue for the first quarter fiscal 2013, an increase of $0.6 million, or 1%, over revenue of $53.0 million for the same period in fiscal 2012. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1792535 Tue 05 Mar 2013 17:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) a leading provider of products and services for the prevention, diagnosis and treatment of disease, announced today that it has launched a new and improved, intuitive, feature-rich TheraSphere® website, providing liver cancer patients and physicians with customized TheraSphere(R) resources that include medical and clinical information, convenient online ordering, and innovative digital resources. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1792198 Tue 05 Mar 2013 08:00:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) a leading provider of products and services to the global health science market, today announced it is appointing Grant Gardiner as Senior Vice President, General Counsel and Corporate Secretary. Mr. Gardiner will serve as the Corporation's legal officer responsible for all global legal matters, effective March 18, 2013. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1778508 Mon 28 Jan 2013 13:01:00 EST Nordion: Global Experience. Global Opportunity http://www.nordion.com/investors/annual_reports.asp Mon 28 Jan 2013 07:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) a leading provider of products and services to the global health science market, today reported results for the fiscal fourth quarter and year ended October 31, 2012. The Company generated $74.7 million in revenue for the fourth quarter fiscal 2012, an increase of $0.7 million, or 1%, over revenue of $74.0 million for the same period in fiscal 2011. Revenue for full year fiscal 2012 was $244.8 million, down 11% from revenue of $274.0 million in fiscal 2011. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1778266 Mon 28 Jan 2013 07:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) a leading provider of products and services for the prevention, diagnosis and treatment of disease, announced today it is hosting an educational symposium titled “The Expanding Role of Radioembolization for the Treatment of Hepatocellular Carcinoma (HCC): Latest Information about Radioembolization, Yttrium-90 (Y-90) Glass Microspheres in HCC and an Update on Phase III Clinical Trials.” The symposium, designed to educate referring physicians, including Medical Oncologists, Hepatologists and Gastroenterologists, is being held at this year’s 2013 Gastrointestinal Cancers Symposium in San Francisco from January 24 – 26, 2013. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1777550 Thu 24 Jan 2013 08:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) a leading provider of products and services to the global health science market, has filed an amended statement of claim against Atomic Energy of Canada Limited (AECL) in the Ontario Superior Court of Justice with regards to the Isotope Production Facilities Agreement (IPFA). The claim requests damages in the amount of $243.5 million for negligence and breach of the IPFA, as well as pre- and post-judgment interest and costs. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1776227 Mon 21 Jan 2013 07:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) today announced it is postponing the release of its fourth quarter and fiscal 2012 financial results and conference call scheduled for December 18 and 19, 2012, respectively. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1766807 Wed 12 Dec 2012 17:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) today provided an update regarding the submissions of arbitration-related costs by Atomic Energy of Canada Limited (AECL) associated with Nordion’s arbitration with AECL over the cancelled MAPLE project. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1764395 Mon, 04 Dec 2012 17:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) announced today that it has been granted special permission by The Open Joint Stock Company "Isotope" (Isotope), the authorized subsidiary of Russia’s State Atomic Energy Corporation "Rosatom" (Rosatom), to enter into a negotiation directly with the Research Institute of Atomic Reactors (RIAR) for supply of Molybdenum-99 (Mo-99). Nordion and Isotope have jointly agreed that the current Mo-99 supply agreement structure was no longer appropriate and have terminated their Mo-99 supply agreement effective Oct. 26, 2012. The 2010 framework agreement with Isotope, to explore and define areas of collaboration for the supply, marketing and sale of isotopes produced in Russia is expected to remain in effect. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1750910 Mon, 29 Oct 2012 07:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) today provided an update regarding proceedings to determine the potential award of costs from Atomic Energy of Canada Limited (AECL) associated with Nordion’s arbitration with AECL over the cancelled MAPLE project. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1747994 Mon, 22 Oct 2012 07:01:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) extended its contract with its primary Medical Isotopes customer, Lantheus Medical Imaging, Inc. (LMI) for the supply of Molybdenum-99 (Mo-99). http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1747981 Mon, 22 Oct 2012 07:00:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) today confirmed that it will cease repurchasing shares under the Normal Course Issuer Bid (NCIB) which will be cancelled effective as of September 19, after close of markets. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1736272 Tue, 18 Sep 2012 17:00:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) today announced a strategic realignment of the business designed to focus on improving the execution of Nordion’s business strategy. The plan includes transitioning Nordion to a Business Unit model with two distinct Business Units: Targeted Therapies and Specialty Isotopes, each of which will be supported by centralized corporate functions. The Specialty Isotopes business will include two segments: Sterilization Technologies and Medical Isotopes. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1734534 Wed, 12 Sep 2012 08:00:00 EST Nordion Inc. (TSX: NDN) (NYSE: NDZ) announced today that it has received the decision in the confidential arbitration with Atomic Energy of Canada Limited (AECL). Nordion was unsuccessful in its claim for specific performance or monetary damages relating to AECL's cancelled construction of the MAPLE facilities. The majority of the tribunal ruled 2:1 that Nordion's claim against AECL in the arbitration was precluded under the terms of the 2006 Interim and Long-Term Supply Agreement (ILTSA) between Nordion and AECL. Thus, Nordion was not entitled to a remedy under the ILTSA for the unilateral termination by AECL of the construction of the MAPLE facilities. http://news.nordion.com/phoenix.zhtml?c=68761&p=irol-newsarticle&ID=1733262 Mon, 10 Sep 2012 08:00:00 EST